Liver Fuction Test and Multi Drugs Resistant (MDR) Tuberculosis: A Review

Main Article Content

Hunny Tyagi
Juhi Aggarwal
Mohamed Javith
Urvashi Midha
Jyoti Batra


The bacterial infection recognized as “tuberculosis (TB)”, which is produced by the complex of “Mycobacterium tuberculosis”, is one of the oldest common diseases and a leading cause of death globally. There is a plan to totally wipe out tuberculosis in India within a decade whilst also 2025. There need to be greater awareness and publicity regarding tuberculosis. This review paper addresses the subjects of history, taxonomy, epidemiology, incidence, treatment tolerance, and liver function. Liver impairment and further therapy have been discussed briefly. In India, the “National Tuberculosis Elimination Project (NTEP)” focuses primarily on “Directly Observed Treatment, Short Course (DOTS)” for preventing the spread of tuberculosis. A case of drug-sensitive or drug-resistant tuberculosis, treatments with certain medications can be hepatotoxic or cause “drug-induced liver injury (DILI)”.

Article Details

How to Cite
Hunny Tyagi, Juhi Aggarwal, Mohamed Javith, Urvashi Midha, & Jyoti Batra. (2023). Liver Fuction Test and Multi Drugs Resistant (MDR) Tuberculosis: A Review. Journal of Coastal Life Medicine, 11(1), 1713–1722. Retrieved from


RaviglioneM,SulisG.Tuberculosis2015:Burden,Challenges and StrategyforControlandElimination.InfectDisRep2016;8:6570.

Cruz A, Starke J. 2014. Tuberculosis, p 1335–1380. In Cherry J, HarrisonG, KaplanS, Steinbach W, Hotez P (ed), Feigin and Cherry’s textbookof pediatric infectiousdiseases.ElsevierSaunders ,Philadelphia,PA

Central TB division, Indian medical association and WHO-INDIA training moduleformedical practitioners.RNTCP Dec2010.

Colon DL, Bustero F, and Raviglione MC. Drugs resistant tuberculosis: review of worldwide situation and the WHO/IUATLD global surveillance project.ClininfectDis 24 1997:S121-30.

Comas I,GagneuxS.Thepast and future of tuberculosis research. PLoSPathog2009;5(10):e1000600 [Internet]

Kallmann F &Reisner D 1942. Twin studies the significance of genetic factors intuberculosis.Am Rev Tuberc, 47: 549-547.

BaddeleyA,DeanA,Monica-DiasH, FalzonD,FloydK,GarciaI.GlobalTuberculosisReport 2013.World HealthOrganization. 2013;306.

R.P. Cusack , L. Chawke , D.J. O’Brien , B. O’Connor and T.M. O’Connor Predictorsof hepatotoxicity among patients treated with antituberculous medication 24September2016.

Ananthnarayan R, Paniker CK. Mycobacterium I: Tuberculosis. In: Textbook ofmicrobiology.8thed universities Press; 2009. P.347-58.

Van soolingen D, Hoogenboezem T, de Haas PE, Hermans PW, KoedamMA,Teppema KS et al. A novel pathogenic taxon of the Mycobacterium tuberculosiscomplex. Canetti: characterization of an exceptional isolate from Africa. Int J SystBacteriol.1997; 47:1236-45.

Vinod Agarwal P.R.Patgaonkar,and S.P Nagaruiya,Tuberculosis of spine,JCraniovertebrJunction spine. F; 74-85

Herzog B.H.“Historyoftuberculosis”.Respiration,1998;65:5-15.

Meulenbeld, G. J., Leiden, E. J. Brilli. “The Madhavanidana and tis chiefcommentary”,1974.

Bhishagratna, K.K.L.S.L. Bhaduri, “An English translation of the SushrutaSamhita”,Calcutta 1916.

AgarwalSP,ChauhanLS,TuberculosiscontrolinIndia,NewDelhi,directorategeneralofhealthservices, Ministryofhealthandfamilywelfare, 2005.

Koch R. Die aetiologie der tuberculose, a translation by Berna Pinner and Max pinnerwithan introduction by Allen K. Krause. Am Rev Tuberc1932; 25:285-323.43.

Daniel TM. Robert Koch and the pathogenesis of tuberculosis. Int J Tuberc lungs dis2005; 9:1181-2.

K.Park.Parkstextbookof preventive andsocialmedicine, 21steditionFeb2011.

Cruz- KnightW,BlakeGumbsL.Tuberculosis:anoverview.PrimCare2013;40(3):743e56 [Internet][cited2014Nov2].

Singh S, Kumar S. Tuberculosis in India: Road to Elimination. Int J Prev Med. 2019 Jun 12;10:114. doi: 10.4103/ijpvm.IJPVM_492_17. PMID: 31360361; PMCID: PMC6592106.

LanACambell, Oumou Bah-sow, pulmonary tuberculosis: diagnosis and treatmentBMI.2006 May20; 332(7551): 1194-7

Dormandy T. The white death. London and Rio grande: The Hambledon Press, 1999;Ied.1-433.

Ramaswamy, SV, Amin, AG, Goksel, S, Stager, CE, Dou, SJ, EL Sahly, H, Musserand JM 2000. Molecular Genetic Analysis of Nucleotide Polymorphisms Associatedwith Ethambutol Resistant in human Isolates ofMycobacteriumtuberculosis.Antimicrobialagents andchemotherapy,44(2):326-336.

Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa [Internet]. Pai M, editor. Vol. 4, PLoS ONE. Public Library of Science (PLoS); 2009. p. e7186

Park YK, Park YS, Na Kl, Cho EH, Shin SS Kim HJ 2013. Increased tuberculosisburden due to demographic transition in Korea from 2001 to 2010. TubercRespir Dis74:104-110.

Krysl j, Korzeniewska-Kosela M, Muller NL, FitGerals JM 1994. Radiologic featuresof pulmonary tuberculosis: an assessment of 188 cases. Can Assoc Radio j 45:101-107

Grossman RF, Hsueh PR, Gillespie SH, Blasi F 2014. Community-acquiredpneumoniaandtuberculosis:differentialdiagnosisandtheuseof fluoroquinolones.IntJInfect Dis,18:14-21

Siddiqi SH, Hwangbo CC 1986. A new antimicrobial mixture (PolymyxinB,amphotericin B, naildixic acid, trimethoprim and azlocillin) for effective suppressionof non-mycobacterial contamination during primary isolation of mycobacteria. ASMAnnualMeeting, Abstract U35.

Hillemann D, Rusch-Gerdes S, Richter E 2005. Application of capilia TB assay ofcultureconfirmation of MTB complex isolates.Int J TubercLung Dis,9:1-3

Centre for Disease Control and Prevention 2009-2014. Updated guideline for the useof nucleic acid amplification test in the diagnosis of tuberculosis. MMWR MorbMortalWkly Rep, 58:7-10.

ZhangY,YewWW2009.MechanismofdrugresistantinMycobacteriumtuberculosis.IntJTuberc Lung Dis, 13: 1320-1330.

Weyar K, Mirzayev F, Migliori GB, Van Gemert W, D’ Ambrosio L, Zignol M 2013.Rapid molecular TB diagnosis evidence, policy making and global implementation ofXpertMTB/RIF. EurRespir J,42:252-71.

YalewMollaMulukenWubetuBekaluDessie (2021).Anti-Tuberculosis DrugInduced Hepatotoxicity and Associated Factors among Tuberculosis Patients atSelectedHospitals, Ethiopia.HepaticMedicine:EvidenceandResearch 2021:13,1-8.

Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomaticpatients, N Engl J Med 2000; 342(17): 1266- 71. [PMID: 10781624 DOI:10.1056/NEJM200004273421707].


362: 887–99.

Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing totreatment adherence and knowledge of TB transmission among patients on TBtreatment.BMC PublicHealth 2004; 4: 68.

WHO. International Monitoring of Adverse Reactions to Drugs: Adverse ReactionTerminology. Uppsala: WHO Collaborating Center for International DrugMonitoring, 1992

Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, BenhamouJP.Isoniazid-rifampinfulminanthepatitis.A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction, Gastroenterology 1977; 72(2): 284-289.

Kulkarni A, Madrasi NA, Relationship of nitric oxide and protein carbonyl intuberculosis,Indian J Tuberc2008; 55(3): 138-44.

Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ,Jollow HR, Keiser HR, Increased incidence of isoniazid hepatitis in rapid acetylators:possible relation to hydranize metabolites, ClinPharmacolTher, 1975; 18(1): 70-79.[PMID:1149365].

Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P, Rifampin-inducedrelease of hydrazine from isoniazidA possible cause of hepatitis during treatment oftuberculosis with regimens containing isoniazid and rifampin, Am Rev Respir Dis.1986;133(6): 1072-1075.

ChaudhuriAD.(2020)Recent changes in guidelines on programmatic management ofdrug resistant tuberculosis in India 2019: a paradigm shift in tuberculosis control TheJournalof Association ofChest Physicians. 8 (2); 53– 63.

Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J (2016). Hepatotoxicity ofantituberculartreatments: rationale for monitoring liver status. Drug Safety; 16: 394–405.

Abbara A, Chitty S, Roe JK ,Ghani R, Collin S, Ritchie A. (2017).Drug-inducedliver injury from antituberculous treatment: a retrospective study from a large TBcentrein theUK. BMC Infectious Diseases; 17: 231-240.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, DekhuijzenR (2008). Anti-tuberculosis drug-induced hepatotoxicity: concise up-to-date review. JGastroenterolHepatol.; 23:192–202

Saha A, Shanthi F X M, Winston A B, Das S, Kumar A, Michael JS, Balamugesh T. Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India. J Prim Care Community Health. 2016 Jul;7(3):171-4. doi: 10.1177/2150131916642431.

Jong, Eefje&Conradie, Francesca &Berhanu, Rebecca & Black, Andrew & John, M-A &Meintjes, G &Menezes, Cassy. (2013). Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. Southern African Journal of HIV Medicine. 14.

Devarbhavi, H., Karanth, D., KS, P., CK, A. and Patil, M. (2011), Drug-Induced liver injury with hypersensitivity features has a better outcome: A single-center experience of 39 children and adolescents. Hepatology, 54: 1344-1350.

Keshavjee S, Gelmanova I. Y, Shin S. S, Mishustin Y S, Andreev P. G, Atwood S,Furin J. J, MillerA. (2012). Hepatotoxicity during treatment for multidrug-resistantTuberculosis:occurrence, management and outcome. Int j tuberc lung dis 16(5): 596–603.